David J. Marguglio - Mar 18, 2022 Form 4 Insider Report for Adamis Pharmaceuticals Corp (ADMP)

Role
SVP and Chief Business Officer, Director
Signature
/s/ David C. Benedicto, as Attorney-in-Fact
Stock symbol
ADMP
Transactions as of
Mar 18, 2022
Transactions value $
-$7,117
Form type
4
Date filed
3/22/2022, 06:39 PM
Previous filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMP Common Stock Sale -$7.12K -11.9K -4.83% $0.60 234K Mar 18, 2022 Direct F1, F2, F3
holding ADMP Common Stock 5.88K Mar 18, 2022 By D. Marguglio as custodian for children.
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The shares were sold to pay the withholding and tax obligations relating to the issuance of shares following the vesting of RSUs previously granted to the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5954 to $0.6143, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 Includes shares of common stock beneficially owned and shares of common stock issuable upon vesting of restricted stock units previously reported in Table 1 of Form 4.